(Q40038407)

16 September 2017

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis (English)

1 reference

16 September 2017

1 reference

1 reference

Jude R Canon

1

1 reference

16 September 2017

Martine Roudier

2

1 reference

16 September 2017

Rebecca Bryant

3

1 reference

16 September 2017

Sean Morony

4

1 reference

16 September 2017

Marina Stolina

5

1 reference

16 September 2017

Paul J Kostenuik

6

1 reference

16 September 2017

William C Dougall

7

1 reference

16 September 2017

5 December 2007

1 reference

Clinical & Experimental Metastasis

16 September 2017

1 reference

16 September 2017

25

1 reference

16 September 2017

2

1 reference

16 September 2017

119-129

1 reference

https://scigraph.springernature.com/pub.10.1007/s10585-007-9127-1

16 September 2017

0 references

cites work

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10585-007-9127-1

Breast cancer cells interact with osteoblasts to support osteoclast formation

21 January 2018

1 reference

12 December 2020

Metastasis to bone: causes, consequences and therapeutic opportunities

1 reference

12 December 2020

Skeletal complications of malignancy

1 reference

12 December 2020

Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway

1 reference

12 December 2020

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma

1 reference

12 December 2020

Osteoclast differentiation and activation

1 reference

12 December 2020

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.

1 reference

12 December 2020

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

12 December 2020

Mechanisms of bone metastasis

1 reference

12 December 2020

Regulation of cancer cell migration and bone metastasis by RANKL.

1 reference

12 December 2020

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

12 December 2020

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

12 December 2020

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

1 reference

12 December 2020

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

12 December 2020

Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo

1 reference

12 December 2020

The RANK/RANKL/OPG triad in cancer-induced bone diseases

1 reference

12 December 2020

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis

1 reference

12 December 2020

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors

1 reference

12 December 2020

The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.

1 reference

12 December 2020

RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini

1 reference

12 December 2020

Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer

1 reference

12 December 2020

A third-generation lentivirus vector with a conditional packaging system

1 reference

12 December 2020

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

1 reference

12 December 2020

Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells

1 reference

12 December 2020

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice

1 reference

12 December 2020

Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton

1 reference

12 December 2020

Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.

1 reference

12 December 2020

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

1 reference

12 December 2020

RANK ligand is a prerequisite for cancer-associated osteolytic lesions

1 reference

12 December 2020

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

12 December 2020

Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line

1 reference

12 December 2020

10.1007/S10585-007-9127-1

Identifiers

DOI

1 reference

Dimensions Publication ID

16 September 2017

0 references

1 reference